Compare Hormel Foods Corp (HRL) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs Heron Therapeutics Inc — how do they compare? Hormel Foods Corp trades at $25.05 (market cap $13.91B), while Heron Therapeutics Inc trades at $0.47 (market cap $91.46M). The key difference: Hormel Foods Corp is far larger — about 152.1× Heron Therapeutics Inc's market cap, and Hormel Foods Corp pays a 4.63% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRL | HRTX | |
|---|---|---|
Market Cap | $13.91B | $91.46M |
Sector | Consumer Staples | Health |
52-Week High | $29.52 | $1.96 |
52-Week Low | $19.74 | $0.39 |
Enterprise Value | $15.91B | $189.36M |
Dividend Yield | 4.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $25.31, down 0.33% on the day, with a bullish technical outlook and consistent earnings beats. The stock shows a P/E of 29.87 and net income margin of 3.82%, supported by a recent dividend of $0.29. Revenue for 2025 was $12.11B, though net income declined to $478.20M. Analysts maintain a mixed consensus with a $26.33 price target, while the company focuses on portfolio streamlining, such as the sale of its Ceratti business in Brazil (PRNewsWire, 2026-06-29).
HRL offers a stable dividend yield and is near multi-year lows, presenting a value opportunity amid sector weakness. Risks include margin pressure from input costs and competitive threats in the consumer staples space. Institutional sentiment is cautious with 57% hold ratings, but technical indicators suggest potential upside if earnings momentum continues.
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
